ThoroughCare | $5,000,000 | (Nov 20, 2024)
OneChronos | $32,000,000 | (Nov 20, 2024)
EarthOptics | $24,000,000 | (Nov 20, 2024)
MimiVax, LLC
United States
- Buffalo, NY
- 10/12/2021
- Unknown
- $5,000,000
Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates
MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer.
SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2 clinical trial in adults with newly diagnosed glioblastoma. Additional indications are being evaluated through Phase 1 clinical trials in multiple myeloma combination with REVLIMID® (lenalidomide) as well as Phase 1 in Neuro-Endocrine Tumors (NET)
- Industry Pharmaceutical Manufacturing
- Website https://www.mimivax.com/
- LinkedIn https://www.linkedin.com/company/mimivax-llc/
Related People
Michael CiesielskiFounder
United States -
Buffalo-Niagara Falls Area
At MimiVax, our mission is to disrupt cancer. To increase survival and send hope through the development of highly innovative immunotherapies aimed at improving patient's lives.
Citizen Health | $14,500,000 | (Nov 20, 2024)
Kong Inc. | $175,000,000 | (Nov 20, 2024)
RIIG | $3,000,000 | (Nov 20, 2024)
OSYTE [O-Sight] | $4,000,000 | (Nov 20, 2024)
Levanta | $20,000,000 | (Nov 20, 2024)
Jimini Health | $8,000,000 | (Nov 20, 2024)
Kalder | $10,500,000 | (Nov 20, 2024)
Lightsynq | $18,000,000 | (Nov 20, 2024)
ChapsVision | $90,000,000 | (Nov 19, 2024)